PFS is superior for patients with IGHV-mutated disease compared with unmutated. As well, for patients with IGHV-mutated disease treated with FCR, relapses appear to be rare after 7 years, suggesting that there may be patients cured by this regimen. MUT, mutated; UNM, unmutated. See Figure 2A in the article by Fischer et al that begins on page 208.